PFIZER INC Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)
PFIZER INC (PFE) had Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) of -$256.00 million as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Summary of Derivative Instruments › Summary of Derivative Instruments by Hedge Designation
us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease · last filed 2026-08-04
- 2026-06-28: Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) -$256.00M.
- 2026-03-29: Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) -$248.00M.
- 2025-12-31: Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) -$163.00M.
- 2025-09-28: Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) -$156.00M.
| Period end | Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) |
|---|---|
| 2026-06-28 | -$256.00M 10-Q · filed 2026-08-04 |
| 2026-03-29 | -$248.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$163.00M 10-Q · filed 2026-08-04 |
| 2025-09-28 | -$156.00M 10-Q · filed 2025-11-04 |
| 2025-06-29 | -$169.00M 10-Q · filed 2025-08-05 |
| 2025-03-30 | -$242.00M 10-Q · filed 2025-05-05 |
| 2024-12-31 | -$384.00M 10-K · filed 2026-02-26 |
| 2024-09-29 | -$24.00M 10-Q · filed 2024-11-04 |
| 2024-06-30 | -$355.00M 10-Q · filed 2024-08-05 |
| 2024-03-31 | -$320.00M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$131.00M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |